Resource Library

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines
NCCN offers up to date clinical practice guidelines for providers caring for patients with breast cancer. To access the guidelines, create a free user account.

American Society of Clinical Oncology (ASCO) Breast Cancer Guidelines
ASCO offers a number of clinical guidelines for providers caring for patients with breast cancer.

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update
This 2021 update provides new recommendations for the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline.

NCCN Guidelines® Updates: Management of Patients with HER2-Negative Breast Cancer
Upon completion of this free continuing medical education activity, healthcare professionals will be able to: "1) Select evidence-based first- and subsequent-line treatment options for patients with metastatic breast cancer based on HR-positive, HER2-negative metastatic breast cancer. 2) List the current therapeutic approaches for management of metastatic triple negative breast cancer. 3) Optimally manage common toxicities related to new agents used to treat metastatic breast cancer."

Oral Agents for Advanced Hormone Receptor Positive Breast Cancer
This free webinar, with available continuing medical education credit, offers the multidisciplinary care team strategies to manage acquisition of, adherence to, and information on treatment-related adverse events of oral drug-inclusive treatment regimens.

Emerging Data are Expanding Treatment Options, Extending Survival Across Breast Cancer Subtypes
Matthew P. Goetz, MD, discusses overall survival data with ribociclib and abemaciclib in estrogen receptor–positive, HER2-negative disease; the role of adjuvant pembrolizumab in patients with triple-negative breast cancer; and the efficacy of PARP inhibitors in earlier settings.

Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development
CDK4/6 inhibitors in the metastatic setting have demonstrated clinical benefit in the hormone receptor–positive breast cancer population, leading to curiosity about their activity in early-stage patients and setting the stage for a handful of informative clinical trials.

Management of Metastatic Breast Cancer with San Antonio Breast Cancer Symposium Updates
Upon completion of this free continuing medical education activity, healthcare professionals will be able to: "1) Select evidence-based first- and subsequent-line treatment options for patients with metastatic breast cancer based on HR-positive, HER2-negative metastatic breast cancer. 2) List the current therapeutic approaches for management of metastatic triple negative breast cancer. 3) Outline new and emerging therapeutic options for patients with HER2-negative metastatic breast cancer. 4) Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer. 5) Optimally manage common toxicities related to the HER2-targeted therapies. 6) Outline new and emerging therapeutic options for patients with HER2-positive metastatic breast cancer.

Metastatic Breast Cancer: Effective Principles & Practices in Patient Support
This ACCC publication includes a communication process map that integrates 6 effective principles into the care continuum, helping to reframe and improve the conversation between providers and patients, and examples of how ACCC Cancer Program members are putting these principles into action to delivery holistic, patient-centered care.

Care Coordination: The Role of Pharmacy to Help Manage Patients with Cancer on Oral Oncolytics
Oral anti-cancer agents are most often administered outside of the clinic, it takes a multidisciplinary team to successfully manage these patients and their treatments. ACCC's “Care Coordination: The Role of Pharmacy to Help Manage Patients with Cancer on Oral Oncolytics,” offers results from a national survey, effective practices to better manage oral anti-cancer medication dispensing and improve patient outcomes, and practice profiles of four cancer programs and their dispensing models.

Tracking Patient Adherence to Oral Anti-Cancer Medication
In this episode of ACCC's CANCER BUZZ podcast, learn how the entire cancer care team can help in promoting safe oral anti-cancer medication adherence by bridging gaps in patient education, management, and monitoring

Patient Assistance & Reimbursement Guide Overview
ACCC's digital Patient Assistance & Reimbursement Guide helps healthcare professionals and patients find the most up-to-date information on the anti-cancer medication assistance and reimbursement programs that are available to help alleviate the financial burden of cancer treatment.

Breast Cancer Nursing Master Class: CDK 4/6 Inhibitors - Translating Evidence Into Nursing Practice
This resource includes a downloadable slide deck, facilitator guide, and kit to support education of both nurses and patients.

Oncology Nursing Society (ONS) Learning Library: CDK4/6 Inhibitors
This learning library features ONS books, courses, clinical practice resources, and articles. Some resources are only accessible through the creation of a free ONS user account.

Oncology Nursing Society (ONS) Oral Adherence Video
"With the increasing number of oral anti-cancer therapies being used in the treatment of cancer it is important that your patient stays adherent. Learn what to assess for prior to starting an oral agent and the signs of non-adherence."

Oncology Nursing Society (ONS) Oral Adherence Toolkit
This ONS toolkit provides a variety of tools for nurses and other healthcare professionals to support patient adherence to oral anti-cancer therapies.

Understanding Your Pathology Report: Breast Cancer
This American Cancer Society webpage helps patients understand medical language you might find in the pathology report.

Frankly Speaking About Cancer: Coping with Metastatic Breast Cancer
This booklet offered by the Cancer Support Community provides information and resources for people living with metastatic breast cancer.

Learn About Metastatic Breast Cancer
This dedicated webpage from Breastcancer.org provides information for patients and loved ones about metastatic breast cancer, tips to manage side effects, clinical trial search, and much more.

Metastatic Breast Cancer: Quality of Life
This fact sheet from Komen provides tips on how to manage side effects from treatement and resources for support.

Preparing for Your Doctor's Visit: A Worksheet for People with Metastatic Breast Cancer
This worksheet offered by the Cancer Support Community helps patients talk with their health care team about symptoms, treatment options, side effects, and getting the emotional and practical support.

What Are CDK4/6 Inhibitors?
This webpage from Breastcancer.org provides information for patients and loved ones about CDK4/6 inhibitors, potential side effects, and tips for patients who are taking a CDK4/6 inhibitor.

Cancer Support Community
Access free support groups, online community, educational resources, and toll-free helpline. "As the largest professionally led non-profit network of cancer support worldwide, the Cancer Support Community is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community."

CancerCare
"Access free comprehensive services including case management, counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer."

SHARE
Access free breast cancer support groups, helpline, online community, and more. "SHARE is a national non-profit dedicated to serving women of all races and cultures, backgrounds and identities. Because no one should have to face breast, ovarian, uterine, cervical or metastatic breast cancer alone."

Susan G. Komen
Access a treatment assistance program, helpline, online community, and other resources. Susan G. Komen's mission "is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer."

Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence
"Currently all approved CDK4/6 inhibitor agents are given orally, issues of patient comprehension of and adherence to prescribed regimens should be at the forefront of practitioners’ concerns about these drugs. In addition, ways to support and facilitate decision-making by patients related to this class of agents and other therapies recently approved for the same indication require focused attention by health-care providers. Oncology has continued to move toward a more patient-specific, precision medicine approach. Likewise, advanced practitioners have the opportunity to identify patient characteristics, preferences, and needs that are unique to individual patients to enhance precision treatment."

Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study
"Barriers to adherence to CDK4/6 inhibitors exist at multiple levels. Our results underscore the potential value of a multilevel intervention (e.g., patient education, evidence-based strategies for symptom management, tips for open and assertive communication with providers, information about financial resources/support available, and so on) to support adherence in this population." Note: This is not an open access article— access will depended upon your institution’s subscription plan.

Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer
"Although knowledge gaps still exist in regard to the optimal sequencing of new regimens, they have expanded our repertoire of options for patients and have shifted the need for cytotoxic chemotherapy and its associated complications to later lines. Still, formatting a plan for these patients includes taking into account traditional prognostic factors... To assist in developing this treatment plan, we will review the current data with systemic agents in the management of these patients."

Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
"Many older women will be treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and an aromatase inhibitor (AI), given US Food and Drug Administration approval of three agents in this class. The current pooled analysis examines the efficacy and safety of this combination in older women."

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
"The purpose of this study is to review CDK 4/6 inhibitors used to treat metastatic breast cancer for patient safety, cost and utilization. By evaluating patient outcomes and payer influence, this study will provide critical information to aid prescribers in therapeutic decisions."